论文部分内容阅读
1WhitehallⅡ研究“揭示2型糖尿病诊断前的代谢轨迹”;2荟萃分析“提供强化降糖有益于减少冠脉事件的证据”;3FIELD研究“非诺贝特减少2型糖尿病患者截肢事件”;4SYNCHRONY研究“PPARα/γ双激动剂的剂量范围探索”;5LEAD-6研究“验证利拉鲁肽安全有效降糖的优势”。第69届美国
1 Whitehall II study “Reveals the metabolic pathways before diagnosis of type 2 diabetes”; 2 Meta-analysis “provides evidence that intensive hypoglycemic benefit reduces coronary events”; 3 Field Study “Fenofibrate reduces amputation in type 2 diabetic patients”; 4SYNCHRONY study “Exploration of the Dose Range of PPARα / γ Double Agonists”; 5 LEAD-6 Study “Validating the Safe and Effective Hypoglycemic Benefit of Liraglutide.” The 69th America